Esperion Therapeutics Inc (ESPR) concluded trading on Wednesday at a closing price of $1.05, with 10.55 million shares of worth about $11.08 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -48.53% during that period and on April 09, 2025 the price saw a loss of about -0.94%. Currently the company’s common shares owned by public are about 195.85M shares, out of which, 194.37M shares are available for trading.
Stock saw a price change of -24.46% in past 5 days and over the past one month there was a price change of -32.26%. Year-to-date (YTD), ESPR shares are showing a performance of -52.27% which decreased to -65.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.04 but also hit the highest price of $3.94 during that period. The average intraday trading volume for Esperion Therapeutics Inc shares is 4.32 million. The stock is currently trading -28.40% below its 20-day simple moving average (SMA20), while that difference is down -36.21% for SMA50 and it goes to -48.62% lower than SMA200.
Esperion Therapeutics Inc (NASDAQ: ESPR) currently have 195.85M outstanding shares and institutions hold larger chunk of about 58.83% of that.
The stock has a current market capitalization of $207.74M and its 3Y-monthly beta is at 0.84. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 0.99. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ESPR, volatility over the week remained 11.81% while standing at 7.52% over the month.
Analysts are in expectations that Esperion Therapeutics Inc (ESPR) stock would likely to be making an EPS of -0.19 in the current quarter, while forecast for next quarter EPS is -0.16 and it is -0.01 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.22 which is -0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.34 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 83.14% while it is estimated to decrease by -349.05% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on December 18, 2024 offering a Neutral rating for the stock and assigned a target price of $4 to it. Coverage by Cantor Fitzgerald stated Esperion Therapeutics Inc (ESPR) stock as an Overweight in their note to investors on December 17, 2024, suggesting a price target of $8 for the stock. Stock get a Neutral rating from JP Morgan on November 20, 2023.
